Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 3/20 | 0.40 |
| ▸ | PRCP | P42785 | 2/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635511 | 0.96 | MEN1 (0.46) | MEN1KMT2AEPHX2TSHRDPP4 | |
| SCHEMBL2637735 | 0.89 | MEN1 (0.52) | MEN1KMT2AEPHX2DPP4LIPE | |
| SCHEMBL2635565 | 0.89 | KDM2B (0.41) | MEN1KMT2APOLBMAPTKDM2B | |
| SCHEMBL2635754 | 0.85 | ALDH1A1 (0.49) | MEN1KMT2AEPHX2TSHRNAMPT | |
| SCHEMBL2635298 | 0.84 | KDM2B (0.41) | MEN1KMT2AKDM2BNAMPT | |
| SCHEMBL2637626 | 0.82 | MEN1 (0.54) | MEN1KMT2AEPHX2DPP4LIPE | |
| SCHEMBL2636148 | 0.82 | PKM (0.51) | MEN1KMT2ATSHRPOLB | |
| SCHEMBL2635794 | 0.81 | ALDH1A1 (0.49) | MEN1KMT2AEPHX2TSHRNAMPT | |
| SCHEMBL2635089 | 0.80 | MEN1 (0.46) | MEN1KMT2AEPHX2TSHRDPP4 | |
| SCHEMBL2635036 | 0.80 | S100A9 (0.40) | MEN1KMT2ATSHRPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | claimed |
| EP-2569317-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2013-03-20 | — | — | EP | claimed |
| WO-2011141728-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | claimed |
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | disclosed |
| EP-2569317-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141728-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141728-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109711-A1 | NOVEL COMPOUNDS | TRPV2, CACNA1C, CACNA1B | MEN1 4056/4885KMT2A 4317/4885EPHX2 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.